Supernus Pharmaceuticals reported $134.57M in Gross Profit on Sales for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
Abbott ABT:US $ 6908M 160M
Aerie Pharmaceuticals AERI:US $ 23.06M 85.54M
Ani Pharmaceuticals ANIP:US $ 30.21M 3.18M
Aurora Cannabis Inc ACB:CN -52930000 16.56M
Bristol Myers Squibb BMY:US $ 9177M 452M
Canopy Growth Corp WEED:CN C$ -159242000 169.33M
Corcept Therapeutics CORT:US $ 92.44M 5.03M
Eisai 4523:JP Y 140163M 18587M
Eli Lilly And LLY:US $ 5737.9M 211.8M
Endo International Ordinary Shares ENDP:US $ 472.5M 94.46M
Horizon Pharma HZNP:US $ 670.18M 102.77M
JAZZ PHA JAZZ:US $ 698.44M 62.14M
Lannett LCI:US $ 3.08M 2.63M
Marinus Pharmaceuticals MRNS:US 13.02M 11.5M
Pacira Pharmaceuticals PCRX:US $ 121.92M 1.73M
Perrigo Ordinary Shares PRGO:US $ 337.8M 24.6M
Pfizer PFE:US $ 15651M 1627M
Revance Therapeutics RVNC:US $ 17.37M 701K
Supernus Pharmaceuticals SUPN:US $ 134.57M 7.48M
Teva Pharmaceutical Industries TEVA:US $ 1802M 323M
United Therapeutics UTHR:US $ 436M 55.4M
Xeris Pharmaceuticals Inc XERS:US $ 15.8M 740K